• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Events

Capitol Hill Briefing – Congressional Malaria & NTD Caucus Briefing

22 February 2010

Washington DC, USA

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

In the US, the Obama Administration releases its 2011 budget asking Congress to approve $155M for the treatment of Neglected Tropical Diseases (NTDs), a $90M increase over 2010. DNDi and MSF are calling for the inclusion of deadly NTDs, such as HAT, VL, and Chagas disease and to include R&D for urgently needed new tools including drugs to replace outdated, toxic, expensive, and ineffective ones. On February 22nd, DNDi, MSF, and RTI hold a briefing on Capitol Hill to inform policymakers of this deadly neglect and the opportunities to save the lives of neglected people suffering from these diseases.

“Controlling Deadly Neglected Tropical Diseases: Opportunities to expand the US impact”

This distinguished panel of non-governmental organizations discussed the needs and opportunities
for the expansion of the US impact on NTDs:

“Success of US NTD Control Program Targeting the 7 ‘Tool-Ready’ NTDs”: Mary Linehan, RTI, NTD Control Program Operations Director

“What about the other fatal NTDs?  Life Saving Opportunities Today”: Dr. Francois Chappuis, Médecins Sans Frontières/Doctors Without Borders (MSF), International Advisor on NTDs

“Game Changing New Treatments in Dr. Manica Balasegaram, Drugs for Neglected Diseases initiative (DNDi), Sr. Clinical Research Manager.


Listen to the broadcast of the briefing!

Neglected Tropical Diseases (NTDs), as defined by the World Health Organization (WHO), are a group of 14 parasitic, bacterial and viral infections, which continue to be a major public health and economic threat to the developing world.  These are the most common infections in the 2.7 billion people living on less than $2 a day.[i] Those affected are often marginalized and forgotten by governments, left to suffer in silence.  Fortunately, control and treatment of these diseases is possible. The current U.S. government initiatives focus on a group of seven NTDs that have inexpensive, safe and effective treatments that are readily available.

However, the NTD Initiative currently excludes seven of the WHO recognized NTDs, including  those that are often fatal if left untreated and have the highest death rates of all of the NTDs:  leishmaniasis (kala azar), sleeping sickness (human African trypanosomiasis or HAT), and Chagas disease.[ii] These diseases, along with Buruli ulcer, are largely left out of control and treatment programs because they are considered too difficult and costly to treat; the available tools are limited; and disease burdens are misunderstood due to inadequate diagnostics and surveillance systems. It is critical that we treat these diseases and develop new treatments and diagnostics now in order to save lives in the future.

The U.S. plays an essential role in leading the international fight against NTDs and its current programs have demonstrated significant success.  The U.S. government must also play a role in the development and introduction of appropriate new tools for NTD control.  Eventually, even those diseases considered to be “tool-ready” today will require new tools in the future. It is necessary to broaden the scope of US programs to include increased investment in Research and Development (R&D) for new tools. Although the National Institutes of Health invests in early stage R&D for some NTDs, USAID has the capability to develop new tools through clinical research and field introduction as they already do for malaria, tuberculosis and HIV/AIDS.  With relatively little additional investment and within the next 5 years, the lives of patients suffering from these NTDs can be saved and several of the sorely needed tools necessary for long term disease control can be developed and introduced.

Hotez PJ, et al., Control of Neglected Tropical Diseases, N Engl J Med 2007, 357:1018-27.

Hotez PJ, et al., Control of Neglected Tropical Diseases, N Engl J Med 2007, 357:1018-27.

Press Release

Read the MSF and DNDi joint press release:
“White House Called on to expand Global Health Initiative : Funding Needed to Combat Most Deadly Neglected Diseases”

Briefing Paper

If you want to learn more about this issue, please read the MSF and DNDi joint briefing paper:
“Fighting Deadly Neglected Tropical Diseases: Opportunities to Expand U.S. Impact in Control of NTDs”

Global Health Initiative

If you want to learn more about the Obama’s administration Global Health Initiative (GHI), please read:
“Implementation of the Global Health Initiative: Consultation Document”

Briefing

If you want to listen to the whole briefing, please visit Doctors Without Borders’ (MSF) webpage:
Congressional Malaria & NTD Caucus Briefing: Controlling Deadly Neglected Tropical Diseases

VoA Article

If you wish to read the article of Voice of America, click here

Letter to USAID

NTDs mentioned in USAID Director Rajiv Shah’s testimony before the House Committee on Foreign Affairs on 2011 US Budget

If you wish to view the video, click on http://www.c-spanvideo.org/program/292349-1 (the NTD question comes in around 31:28).

Below you will find the transcript:

Representative Payne: ….I see you’ve cut 50 million from the Global Fund and I wish you’d look at that….Secondly on NTDs although youre dealing with some of them, the most neglected including the fatal visceral leishmaniasis, sleeping sickness, and Chagas disease; and the disfiguring Buruli ulcer and I wonder if they can be included on that….also on three governance issues, Somalia and the TFG will there be in increase in development aid? we need to increase support…and are we concentrating enough on South Sudan? …finally Liberia needs more consideration….coordination w AfriCom

Dr. Rajiv Shah: On the Global Fund in the context of the GHI we’re committed to increasing significant financial increases against global health and even more using those resources in a more effective way against the lagging indicators in the MDGS such as maternal mortality, and newborn and obstetric care. We’re working with the Global Fund and Global Alliance for Vaccines and other vertical programs to accelerate partnerships between them and get more value out of the overall investment. The overall request on the GF is one billion dollars because it includes the treasury component and we’re committed to helping the GF succeed.

On NTDS, I will take your comments as advisement and look specifically into those cases. That is a unique area where I do believe we can and we have been in discussion with  private partnerships to accelerate public private partnerships and meet the overall needs as they have been delineated by the WHO and others and that is a very much  priority of the GHI.

Letter to USAID

Following the Congressional Malaria & NTD Caucus Briefing, thirteen members of Congress are formally urging USAID to expand R&D funding for treatments for four deadly tropical diseases that impact millions of people in developing countries, yet are largely left out of the Obama Administration’s new Global Health Initiative. The impassioned request was made in a letter sent to Dr. Rajiv Shah, Administrator of the US Agency for International Development on March 23, and is fully in step with the goals of the Drugs for Neglected Diseases initiative.

Read the full letter to USAID

Other events

Loading...
8-12 May 2023

Lisbon, Portugal and online

ESPID 2023

13 April 2023, 2 PM London

London, United Kingdom

Ending the neglect of Chagas disease in the UK

11-12 April 2023

Barcelona, Spain and online

XVIII Jornadas sobre la enfermedad de Chagas

27-31 March 2023

Online

Global meeting on skin-related neglected tropical diseases

See all

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo